Ritlecitinib is under clinical development by Pfizer and currently in Phase II for Celiac Disease. According to GlobalData, Phase II drugs for Celiac Disease does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Ritlecitinib LoA Report. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Likelihood of Approval and Phase Transition Success Rate Model - Ritlecitinib in Celiac Disease

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Ritlecitinib overview

Ritlecitinib (Litfulo) acts as an anti-inflammatory agent. It is formulated as hard capsules for oral route of administration. Litfulo is indicated for the treatment of Alopecia areata for adults and children aged 12 years or older, including alopecia totalis and alopecia universalis, in adults and adolescents 12 years of age and older who are candidates for systemic treatment.
Ritlecitinib (PF-06651600) is under development for the treatment of keloid, rheumatoid arthritis, alopecia areata, Celiac Disease, Crohn's disease, active non-segmental vitiligo, moderate to severe ulcerative colitis, cutaneous t-cell lymphoma subtypes including Sezary syndrome and mycosis fungoides. It is administered orally as a tablet, capsule, solution. It acts by targeting janus kinase 3 (JAK3) and protein kinase Tec (TEC). It is a new molecular entity. It was also under development for rheumatoid arthritis.

Pfizer overview

Pfizer discovers, develops, manufactures, and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular, metabolic and pain, women’s health, cancer, inflammation, immune disorders, and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, individual provider offices, clinics, government agencies, and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. The company provides its products in North America, South America, Asia-Pacific, Australia, Europe, Africa, and the Middle East. Pfizer is headquartered in New York, the US.

For a complete picture of Ritlecitinib’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.